Core Insights - Jasper Therapeutics has initiated dosing in its Phase 1b/2a clinical study, ETESIAN, to evaluate briquilimab for allergic asthma, marking a significant milestone in its clinical programs targeting mast cell-driven diseases [1][2] Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company focused on developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) for chronic mast and stem cell diseases, including chronic urticaria and asthma [5] - Briquilimab has shown efficacy and safety in over 160 participants and healthy volunteers, with clinical outcomes in chronic inducible urticaria (CIndU) and as a conditioning agent in various severe conditions [4][5] Clinical Study Details - The ETESIAN study aims to enroll approximately 30 patients across 7 sites in Canada, utilizing a single 180mg subcutaneous dose of briquilimab [2] - Key objectives include demonstrating proof-of-concept in asthma, assessing early and late asthmatic responses, airway hyperresponsiveness, mast cell depletion, and safety [2][4] Mechanism of Action - Briquilimab functions as a targeted aglycosylated monoclonal antibody that inhibits the binding of stem cell factor to c-Kit, leading to mast cell depletion and potentially alleviating inflammatory responses in mast cell-driven diseases [4][5] - The mechanism of mast cell depletion via c-Kit inhibition is considered novel and may address safety issues seen with other c-Kit inhibitors [3]

Originally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising my background in life sciences to assess the potential of novel treatments, including those using CGT, as well as, their capacity to drive shareholders' returns. Thus, as SA analyst, I will be focusing on analysing biotechnology, pharmac ...

REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences: Stifel 2024 Healthcare ConferenceConference Dates: November 18 – 19, ...

REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended September 30, 2024, provided a corporate update and announced the closure of Jasper's legacy cli ...

REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting data from preclinical studies evaluating briquilimab at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific ...

On Monday, Jasper Therapeutics Inc JSPR stock is trading higher after the company reported preliminary data from its ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria (ColdU) or symptomatic dermographism (SD). Hives (also called urticaria) refer to raised and splotchy areas of skin that can be caused by an allergic reaction. 14 of 15 study participants (93%) enrolled in both dose cohorts (n=15) achieved a clinical response within the 6-week preliminary ...

REDWOOD CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that Health Canada has cleared the Company's Clinical Trial Application (CTA) for a Phase 1b/2a asthma challenge study evaluating b ...

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference Conference D ...

Core Insights - Jasper Therapeutics is making significant progress in the BEACON and SPOTLIGHT studies for briquilimab, with patient enrollment exceeding expectations and additional dosing cohorts being added [1][2][3] Study Progress - Enrollment in the BEACON study is ongoing, with the 240mg single-dose cohort actively enrolling patients and a new 180mg Q8W cohort expected to open for enrollment soon [1][3] - Initial data from the BEACON study, including results from dosing cohorts up to 240mg, is planned for presentation in the fourth quarter of 2024 [2][3] - The SPOTLIGHT study is also progressing, with ongoing enrollment in the second cohort (120mg) and initial data expected to be reported in the fourth quarter of 2024 [3][4] Financial Performance - As of June 30, 2024, the company reported cash and cash equivalents totaling $106.8 million [5] - Research and development expenses for the second quarter of 2024 were $11.3 million, while general and administrative expenses were $4.7 million [5][11] - The net loss for the quarter was $15.0 million, translating to a net loss per share of $0.97 [5][11] Briquilimab Overview - Briquilimab is a targeted monoclonal antibody that inhibits the c-Kit receptor, aiming to treat mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and asthma [6][7] - The drug has shown a promising safety profile and efficacy in over 145 participants and healthy volunteers across various studies [6][7] Future Developments - The company plans to initiate a Phase 1b/2a study in asthma patients in the fourth quarter of 2024 [4] - Jasper is expanding its mast cell portfolio and has hosted webinars to discuss briquilimab's potential in various indications [3][4]

"We are pleased to welcome Svetlana, an experienced and accomplished biopharmaceutical executive, to our Board," said Thomas Wiggans, Chairperson of Jasper's Board. "Svetlana has led several significant partnerships with large pharma and has particular expertise in the areas of strategic planning and business development. We look forward to capitalizing on her insights as the briquilimab development program continues to expand in mast cell diseases. I'd also like to thank Anna French for instrumental contri ...